Cargando…
Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy
STUDY OBJECTIVE: To describe characteristics of postmenopausal women on long-term bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, high), and to determine the prevalence of women eligible for a drug holiday. DESIGN: Retrospective electronic health recor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010634/ https://www.ncbi.nlm.nih.gov/pubmed/24855392 http://dx.doi.org/10.2147/IJWH.S57549 |
_version_ | 1782479886496038912 |
---|---|
author | Kostoff, Matthew D Saseen, Joseph J Borgelt, Laura M |
author_facet | Kostoff, Matthew D Saseen, Joseph J Borgelt, Laura M |
author_sort | Kostoff, Matthew D |
collection | PubMed |
description | STUDY OBJECTIVE: To describe characteristics of postmenopausal women on long-term bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, high), and to determine the prevalence of women eligible for a drug holiday. DESIGN: Retrospective electronic health record review. SETTING: Eight primary care clinics within a university-based health care system. PATIENTS: A total of 201 postmenopausal women of ages 55–89 years, with osteopenia or osteoporosis, prescribed bisphosphonate therapy for >4 years, between October 10, 2002 and September 9, 2012. MAIN RESULTS: The patients’ mean age was 71.4 (±8.2) years; their mean body mass index was 25.3 (±5.6) kg/m(2); and 73.1% were white. Seventy-four out of 201 patients (36.8%) were low-risk; 10/201 (5.0%) were mild-risk; 72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) were high-risk. Eighty-one women (40.3%) were eligible for a drug holiday or discontinuation. The estimated drug cost avoided per eligible patient was $574.80. Calcium and/or vitamin D supplementation was documented in 52.7% of women. CONCLUSION: More than one-third of postmenopausal women taking long-term bisphosphonate therapy had low fracture risk, and over 40% of our patients were eligible for a drug holiday or discontinuation. These data emphasize the need to accurately assess risk and benefit in patients treated with bisphosphonate therapy. |
format | Online Article Text |
id | pubmed-4010634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40106342014-05-22 Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy Kostoff, Matthew D Saseen, Joseph J Borgelt, Laura M Int J Womens Health Original Research STUDY OBJECTIVE: To describe characteristics of postmenopausal women on long-term bisphosphonate therapy who fall into one of four fracture risk categories (low, mild, moderate, high), and to determine the prevalence of women eligible for a drug holiday. DESIGN: Retrospective electronic health record review. SETTING: Eight primary care clinics within a university-based health care system. PATIENTS: A total of 201 postmenopausal women of ages 55–89 years, with osteopenia or osteoporosis, prescribed bisphosphonate therapy for >4 years, between October 10, 2002 and September 9, 2012. MAIN RESULTS: The patients’ mean age was 71.4 (±8.2) years; their mean body mass index was 25.3 (±5.6) kg/m(2); and 73.1% were white. Seventy-four out of 201 patients (36.8%) were low-risk; 10/201 (5.0%) were mild-risk; 72/201 (35.8%) were moderate-risk; and 45/201 (22.4%) were high-risk. Eighty-one women (40.3%) were eligible for a drug holiday or discontinuation. The estimated drug cost avoided per eligible patient was $574.80. Calcium and/or vitamin D supplementation was documented in 52.7% of women. CONCLUSION: More than one-third of postmenopausal women taking long-term bisphosphonate therapy had low fracture risk, and over 40% of our patients were eligible for a drug holiday or discontinuation. These data emphasize the need to accurately assess risk and benefit in patients treated with bisphosphonate therapy. Dove Medical Press 2014-04-28 /pmc/articles/PMC4010634/ /pubmed/24855392 http://dx.doi.org/10.2147/IJWH.S57549 Text en © 2014 Kostoff et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kostoff, Matthew D Saseen, Joseph J Borgelt, Laura M Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title_full | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title_fullStr | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title_full_unstemmed | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title_short | Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
title_sort | evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010634/ https://www.ncbi.nlm.nih.gov/pubmed/24855392 http://dx.doi.org/10.2147/IJWH.S57549 |
work_keys_str_mv | AT kostoffmatthewd evaluationoffractureriskandpotentialdrugholidaysforpostmenopausalwomenonlongtermbisphosphonatetherapy AT saseenjosephj evaluationoffractureriskandpotentialdrugholidaysforpostmenopausalwomenonlongtermbisphosphonatetherapy AT borgeltlauram evaluationoffractureriskandpotentialdrugholidaysforpostmenopausalwomenonlongtermbisphosphonatetherapy |